Featured Story BioCentury & Getty ImagesFDA’s N-of-One call to action for academics

CDER Director Janet Woodcock invites academic researchers to create therapies for individual patients using FDA’s new N-of-One pathway, but she emphasizes the program will not allow companies to skirt ...

Featured Story BioCentury & Getty ImagesNIDA pushes for translational solutions to opioid crisis

One outcome of the flood of attention to the opioid crisis is that it is starting to sway the perception of addiction towards the concept it is a disease, suffered by patients, rather than a behavior, ...

Product Development BioCentury & Getty ImagesSenti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to ...

Product Development BioCentury & Getty ImagesPreprint study renews cancer fears for CRISPR-based therapies

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a ...

Targets & Mechanisms BioCentury & Getty ImagesNew cereblon substrates linked to thalidomide teratogenicity

A Celgene-funded study from Tokyo Medical University and the University of Milan has identified two new thalidomide-dependent CRBN substrates that could be applied to screens for new, safer ...

Emerging Company Profile BioCentury & Getty ImagesErvaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter ...

BioCentury Innovations ISSN 2377-3030